{
    "clinical_study": {
        "@rank": "18315", 
        "arm_group": [
            {
                "arm_group_label": "Risenex M", 
                "arm_group_type": "Experimental", 
                "description": "Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months"
            }, 
            {
                "arm_group_label": "Risenex Plus", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the Efficacy and the Safety of Monthly(RisenexM\n      group) versus Weekly Oral risedronate(Risenexsplus group) in Korean postmenopausal\n      osteoporotic women(Phase IV)"
        }, 
        "brief_title": "To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the Efficacy and the Safety of Monthly(RisenexM\n      group) versus Weekly Oral risedronate(Risenexsplus group) with Vitamin D in compliance,\n      improvement of vitaminD and BMD in Korean postmenopausal osteoporotic women(Phase IV)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female osteoporosis patients over 19years of age(with menopause).\n\n             Definition of osteporosis\n\n               -  They had a BMD T-score -2.5 or less at mean Lumbar spine(L1~L4), Femoral neck or\n                  total. Or evidence of at least one vertebral fracture.\n\n             Definition of menopause(can be one of three condition)\n\n               -  For 12months spontaneous amenorrhea\n\n               -  For 6months spontaneous amenorrhea with serum FSH(Follicle stimulating hormone)\n                  is 40 mlIU/mL and over\n\n               -  6weeks after bilateral ovariectomy whether hysterectomy of not\n\n          2. Patients who can be treated with oral bisphosphonate drugs\n\n          3. Patients who have adequate to be measured DXA(Dual energy x-ray absorptiometry)\n\n          4. Patients who made a voluntary agreement after explanation of this study\n\n          5. Patients who participated in clinical trial(HL_RSNP_401) must have taken the\n             Risenexplus and finish the study for 12 months.\n\n        Exclusion Criteria:\n\n          1. Patients with esophagus disorder.\n\n          2. Patients administered with osteoprosis therapy(except calcium,Vit.D medication)\n             within previous 3 months\n\n          3. Patients with serum calcium concentrations 8.0mg/dL under.\n\n          4. Patients with severe nephropathy(serum creatinine> doulble of normal level\n\n          5. Patients with unable to sit upright or stand 30minutes."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "176", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904110", 
            "org_study_id": "HL_RSNM_401"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Risenex M", 
                    "Risenex Plus"
                ], 
                "description": "once a month", 
                "intervention_name": "Risedronate/Cholecalciferol combination(montly)", 
                "intervention_type": "Drug", 
                "other_name": "Risenex M"
            }, 
            {
                "arm_group_label": "Risenex Plus", 
                "description": "once a week", 
                "intervention_name": "Risedronate/Cholecalciferol combination(weekly)", 
                "intervention_type": "Drug", 
                "other_name": "Risenex Plus"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "Risedronic acid", 
                "Etidronic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Risedronate,cholecalciferol,BMD,montly,weekly,compliance", 
        "lastchanged_date": "July 17, 2013", 
        "location": {
            "contact": {
                "email": "miineunbi.cho@samsung.com", 
                "last_name": "Eunbi Cho", 
                "phone": "82-2-2-3410-1204"
            }, 
            "contact_backup": {
                "email": "andy8686@hanlim.com", 
                "last_name": "Sunyoung Park", 
                "phone": "82-2-3489-6137"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": {
                "last_name": "Youngki Min, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "For 12months, the Multi Center, Randomized, Open-label Comparative Clinical Study to Evaluate the Efficacy and the Safety of Monthly(RisenexM Group) Versus Weekly Oral Risedronate(Risenexsplus Group) With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women(Phase IV)", 
        "overall_contact": {
            "email": "yumi@hanlim.com", 
            "last_name": "Mi Yu", 
            "phone": "82-2-3489-6168"
        }, 
        "overall_contact_backup": {
            "email": "andy8686@hanlim.com", 
            "last_name": "Sunyoung Park", 
            "phone": "82-2-3489-6137"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center Seoul", 
            "last_name": "Youngki Min, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The propotion of patients with 25(Oh)D level <20mg/ml of 12 months", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904110"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The change of Bone Mineral Density(BMD) value[Time frame: 1 year] The change of PTH(Parathyroid hormone value) [Time frame:6months,1 year] The change of Compliance  - overall groups of Risenex plus vs Risenex M(2groups)", 
                "measure": "The change of Bone Mineral Density(BMD) value", 
                "safety_issue": "No", 
                "time_frame": "1year"
            }, 
            {
                "description": "The change of Bone Mineral Density(BMD) value[Time frame: 1 year] The change of PTH(Parathyroid hormone value) [Time frame:6months,1 year] The change of Compliance  - overall groups of Risenex plus vs Risenex M(2groups)", 
                "measure": "The change of PTH(Parathyroid hormone value)", 
                "safety_issue": "No", 
                "time_frame": "6months,1 year"
            }, 
            {
                "description": "The change of Bone Mineral Density(BMD) value[Time frame: 1 year] The change of PTH(Parathyroid hormone value) [Time frame:6months,1 year] The change of Compliance  - overall groups of Risenex plus vs Risenex M(2groups", 
                "measure": "The change of Compliance  - overall groups of Risenex plus vs Risenex M", 
                "safety_issue": "No", 
                "time_frame": "1year"
            }, 
            {
                "measure": "The change of 25(Oh)D level in patients.", 
                "safety_issue": "No", 
                "time_frame": "6months,1year"
            }
        ], 
        "source": "Hanlim Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanlim Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}